Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 367-376

  Vorhies, John S ^a   Nemunaitis, John J ^a  

^a Mary Crowley Cancer Research Centers   (United States)

Author keywords

Aptamer; Cancer; Gene therapy; Oligonucleotides therapeutics; Shrna; Tumor targeting

Indexed keywords

EID: 70449977200     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Aoki R, Tanaka S, et al. 1998. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum, 41(10):1262-72.
2. Apte R, Modi M, Masonson H, et al.; for the Macugen AMD Study Group. 2007. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology, 114(9):1702-12.
3. Bander NH, Milowsky MI, Nanus DM, et al. 2005. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol, 23(21):4591-601.
4. Bates PJ, Kahlon JB, Thomas SD, et al. 1999. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem, 274(37):26369-77.
5. Beigelman L, McSwiggen JA, Draper KG, et al. 1995. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem, 270(43):25702-8.
6. Berchuck A, Kamel A, Whitaker R, et al. 1990. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res, 50(13):4087-91.
7. Boomer RM, Lewis SD, Healy JM, et al. 2005. Conjugation to polyethyl-ene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides, 15(3):183-95.
8. Borsi L, Carnemolla B, Nicolo G, et al. 1992. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer, 52(5): 688-92.
9. Bostwick DG, Pacelli A, Blute M, et al. 1998. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocar-cinoma: a study of 184 cases. Cancer, 82(11):2256-61.
10. Brossart P, Schneider A, Dill P, et al. 2001. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res, 61(18):6846-50.
11. Bunka DH and Stockley PG. 2006. Aptamers come of age at last. Nat Rev
12. Microbiol, 4(8):588-96.
13. Burjonrappa SC, Reddimasu S, Nawaz Z, et al. 2007. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. Indian J Cancer, 44(1):1-5.
14. Burmeister PE, Lewis SD, Silva RF, et al. 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol, 12(1):25-33.
15. Cassiday LA and Maher LJ 3rd. 2001. In vivo recognition of an RNA aptamer by its transcription factor target. Biochemistry, 40(8):2433-8.
16. Cerchia L, Ducongé F, Pestourie C, et al. 2005. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol, 3(4):e123.
17. Chen CH, Chernis GA, Hoang VQ, et al. 2003. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA, 100(16):9226-31.
18. Cheng J, Teply BA, Sherifi I, et al. 2007. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Bioma-terials, 28(5):869-76.
19. Chiquet-Ehrismann, R. 2004. Tenascins. Int J Biochem Cell Biol, 36(6):986-90.
20. Christian S, Pilch J, Akerman ME, et al. 2003. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol, 163(4):871-8.
21. Chu TC, Twu KY, Ellington AD, et al. 2006. Aptamer mediated siRNA delivery. Nucleic Acids Res, 34(10):e73.
22. Cox JC, Hayhurst A, Hesselberth J, et al. 2002. Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res, 30(20):e108.
23. Dapić V, Abdomerović V, Marrington R, et al. 2003. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res, 31(8):2097-107.
24. Dapić V, Bates PJ, Trent JO, et al. 2002. Antiproliferative activity of Gquartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry, 41(11):3676-85.
25. Derenzini M. 2000. The AgNORs. Micron, 31(2):117-20.
26. Derenzini M, Sirri V, Trere D, et al. 1995. The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest, 73(4):497-502.
27. de Smidt PC, Le Doan T, de Falco S, et al. 1991. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res, 19(17):4695-700.
28. Dougall WC, Qian X, Greene MI. 1993. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J Cell Biochem, 53(1):61-73.
29. Dougan H, Lyster DM, Vo CV, et al. 2000. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol, 27(3):289-97.
30. Drolet DW, Nelson J, Tucker CE, et al. 2000. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res, 17(12):1503-10.
31. Dyba M, Tarasova NI, Michejda CJ. 2004. Small molecule toxins targeting tumor receptors. Curr Pharm Des, 10(19):2311-34.
32. Ellington AD, Cox JC, Hayhurst A, et al. 2005. Automated in vitro selection and microarray applications for functional RNA sequences. The RNA World, 3rd Ed., Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press: 683-719.
33. Ellington AD and Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature, 346(6287):818-22.
34. Erickson HP and Bourdon MA. 1989. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol, 5:71-92.
35. Farokhzad OC, Cheng J, Teply BA, et al. 2006. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103(16):6315-20.
36. Farokhzad OC, Jon S, Khademhosseini A, et al. 2004. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res, 64(21):7668-72.
37. Ferreira CS, Matthews CS, Missailidis S. 2006. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol, 27(6):289-301.
38. Freeman LM, Krynyckyi BR, Li Y, et al. 2002. The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer. Q J Nucl Med, 46(2):131-7.
39. Ghosh A and Heston WD. 2004. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem, 91(3):528-39.
40. Ginestier C, Charafe-Jauffret E, Bertucci F, et al. 2002. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol, 161(4):1223-33.
41. Ginisty H, Sicard H, Roger B, et al. 1999. Structure and functions of nucleolin. J Cell Sci, 112(Pt 6):761-72.
42. Gold L, Polisky B, Uhlenbeck O, et al. 1995. Diversity of oligonucleotide functions. Annu Rev Biochem, 64:763-97.
43. Golden MC, Collins BD, Willis MC, et al. 2000. Diagnostic potential of Pho-toSELEX-evolved ssDNA aptamers. J Biotechnol, 81(2-3):167-78.
44. Gopinath SC. 2007. Methods developed for SELEX. Anal Bioanal Chem, 387(1):171-82.
45. Griffin LC, Tidmarsh GF, Bock LC, et al. 1993. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood, 81(12):3271-6.
46. Hansford JR and Mulligan LM. 2000. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet, 37(11):817-27.
47. Held DM, Kissel JD, Patterson JT, et al. 2006. HIV-1 inactivation by nucleic acid aptamers. Front Biosci, 11:89-112.
48. Hicke BJ, Marion C, Chang YF, et al. 2001. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem, 276(52):48644-54.
49. Hicke BJ, Stephens AW, Gould T, et al. 2006. Tumor targeting by an aptamer. J Nucl Med, 47(4):668-78.
50. Hollingsworth MA and Swanson BJ. 2004. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer, 4(1):45-60.
51. Horoszewicz JS, Kawinski E, Murphy GP. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res, 7(5B):927-35.
52. Hough CD, Sherman-Baust CA, Pizer ES, et al. 2000. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 60(22):6281-7.
53. Hovanessian AG, Puvion-Dutilleul F, Nisole S, et al. 2000. The cell-surfaceexpressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res, 261(2):312-28.
54. Hughes JA and Rao GA. 2005. Targeted polymers for gene delivery. Expert Opin Drug Deliv, 2(1):145-57.
55. Ireson CR and Kelland LR. 2006. Discovery and development of anticancer aptamers. Mol Cancer Ther, 5(12):2957-62.
56. Israeli RS, Powell CT, Corr JG, et al. 1994. Expression of the prostatespecific membrane antigen. Cancer Res, 54(7):1807-11.
57. Iwashita T, Kato M, Murakami H, et al. 1999. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene, 18(26):3919-22.
58. Jellinek D, Green LS, Bell C, et al. 1995. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry, 34(36):11363-72.
59. Joo EJ, ten Dam GB, van Kuppevelt TH, et al. 2005. Nucleolin: acharan sulfatebinding protein on the surface of cancer cells. Glycobiology, 15(1):1-9.
60. Kato Y, Minakawa N, Komatsu Y, et al. 2005. New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX. Nucleic Acids Res, 33(9):2942-51.
61. Kohlgraf KG, Gawron AJ, Higashi M, et al. 2003. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res, 63(16):5011-20.
62. Koukoulis GK, Gould VE, Bhattacharyya A, et al. 1991. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol, 22(7):636-43.
63. Laber DA, Sharma VR, Bhupalam L, et al. 2005. Update on the first phase I study of AGRO100 in advanced cancer. J Clin Oncol (Meet Abstr), 23:3064.
64. Laber DA, Taft BS, Kloecker GH, et al. 2006. Extended phase I study of AS1411 in renal and non-small cell lung cancers. J Clin Oncol, 24[18S(June 20 Supplement)]:13098.
65. Lapeyre B, Bourbon H, Amalric F. 1987. Nucleolin, the major nucleolar protein of growing eukaryotic cells: an unusual protein structure revealed by the nucleotide sequence. Proc Natl Acad Sci USA, 84(6):1472-6.
66. Legrand D, Vigié K, Said EA, et al. 2004. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem, 271(2):303-17.
67. Lu Y and Low PS. 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev, 54(5):675-93.
68. Lupold SE, Hicke BJ, Lin Y, et al. 2002. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res, 62(14):4029-33.
69. Mackie EJ, Halfter W, Liverani D. 1988. Induction of tenascin in healing wounds. J Cell Biol, 107(6 Pt 2):2757-67.
70. Maeshima A, Miyagi A, Hirai T, et al. 1997. Mucin-producing adenocarci-noma of the lung, with special reference to goblet cell type adenocar-cinoma: immunohistochemical observation and Ki-ras gene mutation. Pathol Int, 47(7):454-60.
71. McCauley TG, Kurz JC, Merlino PG, et al. 2006. Pharmacologic and phar-macokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm Res, 23(2):303-11.
72. McNamara JO 2nd, Andrechek ER, Wang Y, et al. 2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24(8):1005-15.
73. Moffatt S, Papasakelariou C, Wiehle S, et al. 2006. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Ther, 13(9):761-72.
74. Murphy GP, Elgamal AA, Su SL, et al. 1998. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer, 83(11):2259-69.
75. Ng EW, Shima DT, Calias P, et al. 2006. Pegaptanib, a targeted antiVEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 5(2):123-32.
76. Ohuchi SP, Ohtsu T, Nakamura Y. 2005. A novel method to generate aptamers against recombinant targets displayed on the cell surface. Nucleic Acids Symp Ser (Oxf), (49):351-2.
77. Ohuchi SP, Ohtsu T, Nakamura Y. 2006. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie, 88(7):897-904.
78. Oosterkamp HM, Scheiner L, Stefanova MC, et al. 1997. Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer celllines and demonstration of a new short variant form (MUC-1/Z). Int J Cancer, 72(1):87-94.
79. Orend G. 2005. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol, 37(5):1066-83.
80. Orend G and Chiquet-Ehrismann R. 2006. Tenascin-C induced signaling in cancer. Cancer Lett, 244(2):143-63.
81. Pegram M, Hsu S, Lewis G, et al. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 18(13):2241-51.
82. Perkins AC and Missailidis S. 2007. Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging.
83. Pestourie C, Tavitian B, Duconge F. 2005. Aptamers against extracellular targets for in vivo applications. Biochimie, 87(9-10):921-30.
84. Pietras K, Ostman A, Sjoquist M, et al. 2001. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res, 61(7):2929-34.
85. Rusconi CP, Scardino E, Layzer J, et al. 2002. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419(6902):90-4.
86. Rusconi CP, Roberts JD, Pitoc GA, et al. 2004. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol, 22(11):1423-8.
87. Said EA, Krust B, Nisole S, et al. 2002. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem, 277(40):37492-502.
88. Sarcevic B, Lilischkis R, Sutherland RL. 1997. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem, 272(52):33327-37.
89. Schmidt KS, Borkowski S, Kurreck J, et al. 2004. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res, 32(19):5757-65.
90. Schneider PM, Hung MC, Chiocca SM, et al. 1989. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res, 49(18):4968-71.
91. Shi H, Fan X, Sevilimedu A, et al. 2007. RNA aptamers directed to discrete functional sites on a single protein structural domain. Proc Natl Acad Sci USA, 104(10):374-6.
92. Slamon DJ, Godolphin W, Jones LA, et al. 1989. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905):707-12.
93. Srivastava M and Pollard HB. 1999. Molecular dissection of nucleo-lin's role in growth and cell proliferation: new insights. Faseb J, 13(14):1911-22.
94. Stefanidakis M and Koivunen E. 2004. Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Des, 10(24):3033-44.
95. Storck S, Shukla M, Dimitrov S, et al. 2007. Functions of the histone chaperone nucleolin in diseases. Subcell Biochem, 41:125-44.
96. Su SL, Huang IP, Fair WR, et al. 1995. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res, 55(7):1441-3.
97. Sullenger BA, Gallardo HF, Ungers GE, et al. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 63(3):601-8.
98. Sullenger BA, Gallardo HF, Ungers GE, et al. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol, 65(12):6811-6.
99. Taylor-Papadimitriou J, Burchell J, Miles DW, et al. 1999. MUC1 and cancer. Biochim Biophys Acta, 1455(2-3):301-13.
100. Tuerk C and Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249(4968):505-10.
101. Umehara T, Fukuda K, Nishikawa F, et al. 2004. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp Ser (Oxf), (48):195-6.
102. Vater A, Jarosch F, Buchner K, et al. 2003. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res, 31(21):e130.
103. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, et al. 2000. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers, 15(4):343-56.
104. White RR, Sullenger BA, Rusconi CP. 2000. Developing aptamers into therapeutics. J Clin Invest, 106(8):929-34.
105. Willis MC, Collins BD, Zhang T, et al. 1998. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem, 9(5):573-82.
106. Yokota J, Yamamoto T, Miyajima N, et al. 1988. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene, 2(3):283-7.
107. Zagzag D, Friedlander DR, Miller DC, et al. 1995. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res, 55(4):907-14.
108. Zhang S, Zhang HS, Reuter VE, et al. 1998. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res, 4(2):295-302.